As shown in Figure 5A-D, the ERK inhibitor effectively and completely suppressed the phosphorylation of ERK and NFκB induced by CML treatment, highlighting the critical role of ERK in this signaling cascade. Here, NFKB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.